ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式(ヒル表記法):
C11H18N4O3
CAS番号:
分子量:
254.29
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
製品名
ピモニダゾール, ≥98% (HPLC)
SMILES string
OC(CN1CCCCC1)Cn2ccnc2[N+]([O-])=O
InChI key
WVWOOAYQYLJEFD-UHFFFAOYSA-N
InChI
1S/C11H18N4O3/c16-10(8-13-5-2-1-3-6-13)9-14-7-4-12-11(14)15(17)18/h4,7,10,16H,1-3,5-6,8-9H2
assay
≥98% (HPLC)
form
powder
color
yellow
solubility
DMSO: >20 mg/mL
storage temp.
2-8°C
Quality Level
関連するカテゴリー
Biochem/physiol Actions
ピモニダゾールは、位置2にニトロ基とイミダゾール環を有します。ピモニダゾールは還元され、低酸素の細胞中で活性化されます。
ピモニダゾールは、効果的かつ非毒性で外因性の2-ニトロイミダゾール低酸素症マーカーです。
ピモニダゾールは、効果的で非毒性の外因性2-ニトロイミダゾール低酸素マーカーです。ピモニダゾールは、タンパク質、ペプチドおよびアミノ酸のチオール基と付加体を形成します。
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Yong Chen et al.
Disease models & mechanisms, 12(12) (2019-11-11)
Major risk factors for necrotizing enterocolitis (NEC) are formula feeding and prematurity; however, their pathogenic mechanisms are unknown. Here, we found that insufficient arginine/nitric oxide synthesis limits blood flow in the intestinal microvasculature, leading to hypoxia, mucosal damage and NEC
Lena-Christin Conradi et al.
Angiogenesis, 20(4), 599-613 (2017-09-07)
Blockade of the glycolytic activator PFKFB3 in cancer cells (using a maximum tolerable dose of 70 mg/kg of the PFKFB3 blocker 3PO) inhibits tumor growth in preclinical models and is currently being tested as a novel anticancer treatment in phase I
Hanneke Stegeman et al.
Head & neck, 36(9), 1288-1295 (2014-03-29)
Hypoxia, metabolism, and growth factor signaling are important prognostic features in most solid tumors. The purpose of this study was to determine whether head and neck squamous cell carcinoma (HNSCC) xenografts show similar biological and molecular characteristics as the primary
Hypoxia Studies with Pimonidazole in vivo
Aguilera KY and Brekken RA
Bio-protocol, 4(19) (2014)
Esther A Kleibeuker et al.
Oncotarget, 7(47), 76613-76627 (2016-10-27)
The extent of tumor oxygenation is an important factor contributing to the efficacy of radiation therapy (RTx). Interestingly, several preclinical studies have shown benefit of combining RTx with drugs that inhibit tumor blood vessel growth, i.e. angiostatic therapy. Recent findings
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)